Search Results - "Tiedt, Ralph"

Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo by Tiedt, Ralph, Schomber, Tibor, Hao-Shen, Hui, Skoda, Radek C.

“…To generate transgenic mice that express Cre-recombinase exclusively in the megakaryocytic lineage, we modified a mouse bacterial artificial chromosome (BAC)…”
Get full text

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice by Tiedt, Ralph, Hao-Shen, Hui, Sobas, Marta A., Looser, Renate, Dirnhofer, Stephan, Schwaller, Jürg, Skoda, Radek C.

“…An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic…”
Get full text

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model by Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, deWeck, Antoine, Rad, Roland, Barys, Louise, Jeay, Sebastien, Ferretti, Stephane, Kauffmann, Audrey, Sutter, Esther, Grevot, Armelle, Moulin, Pierre, Murakami, Masato, Sellers, William R., Hofmann, Francesco, Jensen, Michael Rugaard

“…Inhibitors of double minute 2 protein (MDM2)–tumor protein 53 (TP53) interaction are predicted to be effective in tumors in which the TP53 gene is wild type,…”
Get full text

Talin is required for integrin-mediated platelet function in hemostasis and thrombosis by Petrich, Brian G, Marchese, Patrizia, Ruggeri, Zaverio M, Spiess, Saskia, Weichert, Rachel A M, Ye, Feng, Tiedt, Ralph, Skoda, Radek C, Monkley, Susan J, Critchley, David R, Ginsberg, Mark H

“…Integrins are critical for hemostasis and thrombosis because they mediate both platelet adhesion and aggregation. Talin is an integrin-binding cytoplasmic…”
Get full text

Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion by Léon, Catherine, Eckly, Anita, Hechler, Béatrice, Aleil, Boris, Freund, Monique, Ravanat, Catherine, Jourdain, Marie, Nonne, Christelle, Weber, Josiane, Tiedt, Ralph, Gratacap, Marie-Pierre, Severin, Sonia, Cazenave, Jean-Pierre, Lanza, François, Skoda, Radek, Gachet, Christian

“…Mutations in the MYH9 gene encoding the nonmuscle myosin heavy chain IIA result in bleeding disorders characterized by a macrothrombocytopenia. To understand…”
Get full text

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach by Chen, Chao, Zhu, Hugh, Stauffer, Frédéric, Caravatti, Giorgio, Vollmer, Susanne, Machauer, Rainer, Holzer, Philipp, Möbitz, Henrik, Scheufler, Clemens, Klumpp, Martin, Tiedt, Ralph, Beyer, Kim S, Calkins, Keith, Guthy, Daniel, Kiffe, Michael, Zhang, Jeff, Gaul, Christoph

“…Oncogenic MLL fusion proteins aberrantly recruit Dot1L, a histone methyltransferase, to ectopic loci, leading to local hypermethylation of H3K79 and…”
Get full text

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket by Scheufler, Clemens, Möbitz, Henrik, Gaul, Christoph, Ragot, Christian, Be, Céline, Fernández, César, Beyer, Kim S, Tiedt, Ralph, Stauffer, Frédéric

“…Mixed lineage leukemia (MLL) gene rearrangement induces leukemic transformation by ectopic recruitment of disruptor of telomeric silencing 1-like protein…”
Get full text

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach by Möbitz, Henrik, Machauer, Rainer, Holzer, Philipp, Vaupel, Andrea, Stauffer, Frédéric, Ragot, Christian, Caravatti, Giorgio, Scheufler, Clemens, Fernandez, Cesar, Hommel, Ulrich, Tiedt, Ralph, Beyer, Kim S, Chen, Chao, Zhu, Hugh, Gaul, Christoph

“…Misdirected catalytic activity of histone methyltransferase Dot1L is believed to be causative for a subset of highly aggressive acute leukemias. Targeting the…”
Get full text

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma by Qin, Shukui, Chan, Stephen Lam, Sukeepaisarnjaroen, Wattana, Han, Guohong, Choo, Su Pin, Sriuranpong, Virote, Pan, Hongming, Yau, Thomas, Guo, Yabing, Chen, Minshan, Ren, Zhenggang, Xu, Jianming, Yen, Chia-Jui, Lin, Zhong-Zhe, Manenti, Luigi, Gu, Yi, Sun, Yongjian, Tiedt, Ralph, Hao, Lu, Song, Wenjie, Tanwandee, Tawesak

“…Background: The objectives of this phase II study were to determine the clinical activity of the MET tyrosine kinase inhibitor capmatinib (INC280) in patients…”
Get full text

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition by Fassl, Anne, Brain, Christopher, Abu-Remaileh, Monther, Stukan, Iga, Butter, Deborah, Stepien, Piotr, Feit, Avery S, Bergholz, Johann, Michowski, Wojciech, Otto, Tobias, Sheng, Qing, Loo, Alice, Michael, Walter, Tiedt, Ralph, DeAngelis, Carmine, Schiff, Rachel, Jiang, Baishan, Jovanovic, Bojana, Nowak, Karolina, Ericsson, Maria, Cameron, Michael, Gray, Nathanael, Dillon, Deborah, Zhao, Jean J, Sabatini, David M, Jeselsohn, Rinath, Brown, Myles, Polyak, Kornelia, Sicinski, Piotr

“…Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor-positive breast cancers. In contrast, triple-negative…”
Get full text

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway by Dafflon, Caroline, Gaulis, Swann, Barys, Louise, Kapur, Karen, Cornacchione, Vanessa, Schukur, Lina, Bergling, Sebastian, Traggiai, Elisabetta, Jansky, Selina, Hellmann, Leon, Engstler, Barbara Schacher, Kerr, Grainne, de Weck, Antoine, Ruddy, David A, Naumann, Ulrike, Stauffer, Frédéric, Gaul, Christoph, Lin, Ying, Billy, Eric, Weiss, Andreas, Hofmann, Francesco, Ito, Moriko, Tiedt, Ralph

“…The histone 3 lysine 79 (H3K79) methyltransferase (HMT) DOT1L is known to play a critical role for growth and survival of -rearranged leukemia. Serendipitous…”
Get full text

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression by Chapeau, Emilie A, Mandon, Emeline, Gill, Jason, Romanet, Vincent, Ebel, Nicolas, Powajbo, Violetta, Andraos-Rey, Rita, Qian, Zhiyan, Kininis, Miltos, Zumstein-Mecker, Sabine, Ito, Moriko, Hynes, Nancy E, Tiedt, Ralph, Hofmann, Francesco, Eshkind, Leonid, Bockamp, Ernesto, Kinzel, Bernd, Mueller, Matthias, Murakami, Masato, Baffert, Fabienne, Radimerski, Thomas

“…Aberrant activation of the JAK/STAT pathway is thought to be the critical event in the pathogenesis of the chronic myeloproliferative neoplasms, polycythemia…”
Get full text

Zim17, a Novel Zinc Finger Protein Essential for Protein Import into Mitochondria by Burri, Lena, Vascotto, Katherine, Fredersdorf, Steffen, Tiedt, Ralph, Hall, Michael N., Lithgow, Trevor

“…Translocation of precursor proteins across the mitochondrial membranes requires the coordinated action of multisubunit translocases in the outer and inner…”
Get full text

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family by Liu, Kun, Kralovics, Robert, Rudzki, Zbigniew, Grabowska, Barbara, Buser, Andreas S, Olcaydu, Damla, Gisslinger, Heinz, Tiedt, Ralph, Frank, Patricia, Okon, Krzysztof, van der Maas, Anthonie P.C, Skoda, Radek C

“…1 Experimental Hematology, Department of Biomedicine, Basel University Hospital, Basel, Switzerland 2 Department of Pathomorphology, Collegium Medicum,…”
Get full text

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening by McDonald, E. Robert, de Weck, Antoine, Schlabach, Michael R., Billy, Eric, Mavrakis, Konstantinos J., Hoffman, Gregory R., Belur, Dhiren, Castelletti, Deborah, Frias, Elizabeth, Gampa, Kalyani, Golji, Javad, Kao, Iris, Li, Li, Megel, Philippe, Perkins, Thomas A., Ramadan, Nadire, Ruddy, David A., Silver, Serena J., Sovath, Sosathya, Stump, Mark, Weber, Odile, Widmer, Roland, Yu, Jianjun, Yu, Kristine, Yue, Yingzi, Abramowski, Dorothee, Ackley, Elizabeth, Barrett, Rosemary, Berger, Joel, Bernard, Julie L., Billig, Rebecca, Brachmann, Saskia M., Buxton, Frank, Caothien, Roger, Caushi, Justina X., Chung, Franklin S., Cortés-Cros, Marta, deBeaumont, Rosalie S., Delaunay, Clara, Desplat, Aurore, Duong, William, Dwoske, Donald A., Eldridge, Richard S., Farsidjani, Ali, Feng, Fei, Feng, JiaJia, Flemming, Daisy, Forrester, William, Galli, Giorgio G., Gao, Zhenhai, Gauter, François, Gibaja, Veronica, Haas, Kristy, Hattenberger, Marc, Hood, Tami, Hurov, Kristen E., Jagani, Zainab, Jenal, Mathias, Johnson, Jennifer A., Jones, Michael D., Kapoor, Avnish, Korn, Joshua, Liu, Jilin, Liu, Qiumei, Liu, Shumei, Liu, Yue, Loo, Alice T., Macchi, Kaitlin J., Martin, Typhaine, McAllister, Gregory, Meyer, Amandine, Mollé, Sandra, Pagliarini, Raymond A., Phadke, Tanushree, Repko, Brian, Schouwey, Tanja, Shanahan, Frances, Shen, Qiong, Stamm, Christelle, Stephan, Christine, Stucke, Volker M., Tiedt, Ralph, Varadarajan, Malini, Venkatesan, Kavitha, Vitari, Alberto C., Wallroth, Marco, Weiler, Jan, Zhang, Jing, Mickanin, Craig, Myer, Vic E., Porter, Jeffery A., Lai, Albert, Bitter, Hans, Lees, Emma, Keen, Nicholas, Kauffmann, Audrey, Stegmeier, Frank, Hofmann, Francesco, Schmelzle, Tobias, Sellers, William R.

“…Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant…”
Get full text

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation by Baltschukat, Sabrina, Engstler, Barbara Schacher, Huang, Alan, Hao, Huai-Xiang, Tam, Angela, Wang, Hui Qin, Liang, Jinsheng, DiMare, Matthew T, Bhang, Hyo-Eun Carrie, Wang, Youzhen, Furet, Pascal, Sellers, William R, Hofmann, Francesco, Schoepfer, Joseph, Tiedt, Ralph

“…The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the…”
Get full text

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma by Goyal, Lipika, Saha, Supriya K, Liu, Leah Y, Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G, Lennerz, Jochen K, Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E, Gurski, Jr, Joseph M, Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P, Stone, James R, Iafrate, A John, Getz, Gad, Porta, Diana Graus, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B, Bardeesy, Nabeel, Zhu, Andrew X

“…Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic…”
Get more information

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts by Perner, Florian, Gadrey, Jayant Y., Xiong, Yijun, Hatton, Charles, Eschle, Benjamin K., Weiss, Andreas, Stauffer, Frédéric, Gaul, Christoph, Tiedt, Ralph, Perry, Jennifer A., Armstrong, Scott A., Krivtsov, Andrei V.

“…Publisher's Note: There is a Blood Commentary on this article in this issue…”
Get full text

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models by Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G, Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R, Caponigro, Giordano

“…Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6…”
Get full text

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR + Advanced Breast Cancer by Tolaney, Sara M, Im, Young-Hyuck, Calvo, Emiliano, Lu, Yen-Shen, Hamilton, Erika, Forero-Torres, Andres, Bachelot, Thomas, Maur, Michela, Fasolo, Angelica, Tiedt, Ralph, Nardi, Lisa, Stammberger, Uz, Abdelhady, Ahmed M, Ruan, Shiling, Lee, Soo Chin

“…Resistance to treatment with endocrine therapy in patients with HR , HER2 advanced breast cancer (ABC) is common and dual inhibition of CDK4/6 and PI3K…”
Get full text